Tumor Molecular Profiling

Learn More About Tumor Molecular Profiling: Chat with Us | Email Us

Molecular Testing

Dr. Ritwick Panicker, a medical oncologist and hematologist at Cancer Treatment Centers of America, explains molecular testing and how it enables doctors to personalize cancer treatment.

Advanced Diagnostic: Tumor Molecular Profiling

Our goal at Cancer Treatment Centers of America (CTCA) is to develop a cancer treatment plan personalized to your needs. We perform tumor molecular profiling to identify chemotherapy drugs and other targeted therapies that have clinical benefits and may be more likely to work for you.

By choosing more effective drugs, we can avoid unnecessary toxicity to you and target cancer cells as aggressively as possible from the start.

Our oncologists use tumor molecular profiling to:

Identify the unique the molecular “blueprint” of each patient’s tumor.
Choose cancer treatments that are more likely to be effective and rule out those that are unlikely to be effective, on an individual patient basis – minimizing trial and error.
Discover potentially beneficial treatment options that may not have been considered in an initial treatment plan.

What Is Molecular Profiling?

Every cancer cell has its own pattern of active genes and proteins. Molecular profiling tests for a variety of biomarkers in the DNA of a tissue sample to help us better diagnose, stage and treat cancer on an individualized basis.

We use CarisTarget Now™ Molecular Profiling, a comprehensive tumor analysis test that matches therapies to your specific biomarker information to develop an evidence- based treatment plan.

If you have a solid tumor, we’ll try to get a sample of tissue during a biopsy or surgery . Then, we’ll test for the presence of a variety of enzymes, proteins and genes to identify which therapies are likely to be most effective.

By comparing the tumor's information with data from thousands of clinical cancer research studies, the test identifies which treatments are likely to be most effective and which treatments are likely to be ineffective. This provides us with more and better information to develop a personalized treatment plan for you.

Who Is Right for Target Now?

Patients with solid tumors.
Patients with highly aggressive cancers that may not respond or have not responded to standard of care therapies.
Patients with rare tumor types.